Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

ZP2307, a novel, cyclic PTH(1-17) analog that augments bone mass in ovariectomized rats

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Preserved postprandial suppression of bone turnover markers, despite increased fasting levels, in postmenopausal women

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. High serum FSH is not a risk factor for low bone mineral density in infertile men

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Possible link between FSH and RANKL release from adipocytes in men with impaired gonadal function including Klinefelter syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Systemisk og lokal allergi over for humant insulin

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Trine Skovlund Ryge Neerup
  • Martin Stahlhut
  • Jørgen S Petersen
  • Jens Rejnhold Daugaard
  • Jens-Erik B Jensen
  • Zhiqi Peng
  • Jukka Morko
  • Christian Thorkildsen
View graph of relations
Daily injections of human parathyroid hormone (1-34), hPTH(1-34), provide a highly effective treatment option for severe osteoporosis. However, PTH analogs shorter than 28 amino acids do not retain any bone augmenting potential. Here, we present ZP2307 ([Ac₅c¹, Aib³, Leu⁸, Gln¹⁰, Har¹¹, Ala¹², Trp¹⁴, Asp¹⁷]PTH(1-17)-NH₂), a novel, chemically modified and cyclized hPTH(1-17) analog, that augments bone mass in ovariectomized, osteopenic rats. Subcutaneous administration of this structurally constrained, K¹³-D¹⁷ side-chain-to-side-chain cyclized peptide reversed bone loss and increased bone mineral density (BMD) up to or above baseline levels in rat long bones and vertebrae. Highly significant effects of ZP2307 were achieved at doses of 40-320 nmol/kg. Micro-CT and histomorphometric analyses showed that ZP2307 improved quantitative and qualitative parameters of bone structure. Biomechanical testing of rat femora confirmed that ZP2307 dramatically increased bone strength. Over a broad maximally effective dose range (40-160 nmol/kg) ZP2307 did not increase serum concentrations of ionized free calcium above normal levels. Only at the highest dose (320 nmol/kg) ZP2307 induced hypercalcemic calcium levels in the ovariectomized rats. To our knowledge ZP2307 is the smallest PTH peptide analog known to exert augmentation of bone. Our findings suggest that ZP2307 has the potential to effectively augment bone mass over a broad dose range without a concomitant increase in the serum concentration of ionized free calcium above the normal range.
Original languageEnglish
JournalBone
Volume48
Issue number6
Pages (from-to)1319-27
Number of pages9
ISSN8756-3282
DOIs
Publication statusPublished - 2011

    Research areas

  • Absorptiometry, Photon, Animals, Bone Density, Bone Density Conservation Agents, Bone and Bones, Calcium, Cyclic AMP, Female, Organ Size, Ovariectomy, Parathyroid Hormone, Peptide Fragments, Rats, Rats, Inbred F344, Tomography, X-Ray Computed

ID: 34920861